Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Current Deferred Revenue (2020 - 2026)

Maxcyte has reported Current Deferred Revenue over the past 6 years, most recently at $3.6 million for Q4 2025.

  • Quarterly Current Deferred Revenue fell 31.48% to $3.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.6 million through Dec 2025, down 31.48% year-over-year, with the annual reading at $3.6 million for FY2025, 31.48% down from the prior year.
  • Current Deferred Revenue was $3.6 million for Q4 2025 at Maxcyte, down from $5.2 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $7.3 million in Q2 2022 and troughed at $2.6 million in Q2 2025.
  • The 5-year median for Current Deferred Revenue is $5.6 million (2023), against an average of $5.4 million.
  • Year-over-year, Current Deferred Revenue soared 39.31% in 2021 and then plummeted 35.81% in 2023.
  • A 5-year view of Current Deferred Revenue shows it stood at $6.7 million in 2021, then fell by 0.5% to $6.7 million in 2022, then dropped by 24.49% to $5.1 million in 2023, then grew by 3.59% to $5.3 million in 2024, then plummeted by 31.48% to $3.6 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Current Deferred Revenue are $3.6 million (Q4 2025), $5.2 million (Q3 2025), and $2.6 million (Q2 2025).